ArticleScientific reports2025
Bioactivity and toxicity of polysaccharides derived from the phytopathogenic mushroom Ganoderma orbiforme cultured in a bioreactor.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The phytopathogenic status of G. orbiforme as the causative agent of basal stem rot on oil palm has masked its biotechnological potential. This study explored its growth profile in an Air-L-Shaped Bioreactor along with the antibacterial and antioxidant activities of its extracellular (EPS) and intracellular polysaccharides (IPS), and evaluated their toxicity using the zebrafish embryo toxicity (ZFET) assay. The biomass pellet peaked at 2.53 ± 0.44 g/L, with EPS and IPS yields reaching 0.15 ± 0.06 g/L (Day 6) and 0.06 ± 0.01 g/L (Day 10), respectively. Morphological observations revealed that the hairy starburst-shaped pellet correlated with peak EPS release. Then, the antibacterial assays revealed EPS as the better antibacterial agent compared to IPS, highlighted by a broader spectrum activity with the most prominent inhibition against Streptomyces griseus and Staphylococcus epidermidis with a minimum inhibitory concentration of 5 mg/mL. Both EPS and IPS showed strong antioxidative capabilities, demonstrated in DPPH assay-IC
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.